Advertisement

Acta Endoscopica

, 30:377 | Cite as

Place de la tomographie d'émission à positron en gastro-entérologie

  • J. Monteil
  • S. Verbeke
  • T. Ducloux
  • D. Sautereau
  • A. Gainant
  • B. Descottes
  • R. Perdrisot
  • J. C. Vandroux
Article
  • 31 Downloads

Conclusion

La TEP apparaît aujourd'hui comme une technique incontournable en cancérologie. Associée aux autres modalités d'imagerie, elle permet des bilans très précis dans la stadification initiale et les récurrences d'un grand nombre d'affections malignes. Sur le plan médico-économique, elle permettra probablement, comme le démontre un certain nombre de publications américaines, des économies substantielles obtenues essentiellement en évitant des chirurgies inutiles. En cas de chirurgie possible, on pourra utiliser des sondes per-opératoires dans le but d'obtenir une exérèse complète.

L'importance de la fixation du18FDG étant directement liée à l'évolutivité des lésions, la TEP apparaît également comme un excellent moyen de contrôle de l'efficacité d'une chimiothérapie et ceci dès la première ou deuxième cure [25].

Mots-clés

cancer 18FDG gastro-entérologie TEP 

Positron emission tomography: indications in gastroenterology

Key-words

cancer 18FDG gastroenterology TEP 

Références

  1. 1.
    AKHURST T., LARSON S.M.—Positron emission tomography imaging of colorectal cancer.Semin. Oncol., 1999 Oct.,26 (5), 577–583.PubMedGoogle Scholar
  2. 2.
    BENDER H., BANGARD N., METTEN N., BANGARD M., MEZGER J., SCHOMBURG A.—Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer.Hybridoma, 1999 Feb.,18(1), 87–91.PubMedCrossRefGoogle Scholar
  3. 3.
    BENYOUNES H., SMITH F.W., CAMPBELL C., EVANS N.T., NORTON M.Y., MIKECZ P., HEYS S.D., BRUCE D., EREMIN O., SHARP P.F.—Superimposition of PET images using 18F-fluorodeoxyglucose with magnetic resonance images in patients with pancreatic carcinoma.Nucl. Med. Commun., 1995 Jul.,16(7), 575–580.PubMedCrossRefGoogle Scholar
  4. 4.
    BOYKIN K.N., ZIBARI G.B., LILIEN D.L., McMILLAN R.W., AULTMAN D.F., McDONALD J.C.—The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver.Am. Surg., 1999 Dec.,65 (12), 1183–1185.PubMedGoogle Scholar
  5. 5.
    COMBS C.S., BRUNT E.M., LOWE V.J., WOLVERSON M.K., SOLOMON H., COLLINS B.T., DI BISCEGLIE A.M. —Positron emission tomography scanning in the evaluation of hepatocellular carcinoma.J. Hepatol., 2000 May,32 (5), 792–797.PubMedCrossRefGoogle Scholar
  6. 6.
    DELBEKE D., ROSE D.M., CHAPMAN W.C., PINSON C.W., WRIGHT J.K., BEAUCHAMP R.D., SHYR Y., LEACH S.D.—Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.J. Nucl. Med., 1999 Nov,40(11), 1784–1791.PubMedGoogle Scholar
  7. 7.
    DELBEKE D., MARTIN W.H., SANDLER M.P., CHAPMAN W.C., WRIGHT J.K.J.R., PINSON C.W.—Evaluation of benign vs malignant hepatic lesions with positron emission tomography.Arch. Surg. 1998 May,133 (5), 510–515; discussion, 510–516.PubMedCrossRefGoogle Scholar
  8. 8.
    FLAMEN P., STROOBANTS S., VAN CUTSEM E., DUPONT P., BORMANS G., DE VADDER N., PENNINCKX F., VAN HOE L., MORTELMANS L.—Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer.J. Clin. Oncol., 1999 Mar,17(3), 894–901.PubMedGoogle Scholar
  9. 9.
    FLANAGAN F.L., DEHDASHTI F., SIEGEL B.A., TRASK D.D., SUNDARESAN S.R., PATTERSON G.A., COOPER J.D.—Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography.AJR Am. J. Roentgenol., 1997 Feb.,168(2), 417–424.PubMedGoogle Scholar
  10. 10.
    FONG Y., SALDINGER P.F., AKHURST T., MACAPINLAC H., YEUNG H., FINN R.D., COHEN A., KEMENY N., BLUMGART L.H., LARSON S.M.—Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases.Am. J. Surg., 1999 Oct.,178(4), 282–287.PubMedCrossRefGoogle Scholar
  11. 11.
    FRANKE C., KLAPDOR R., MEYERHOFF K., SCHAUMAN M. —18-FDG positron emission tomography of the pancreas: diagnostic benefit in the follow-up of pancreatic carcinoma.Anticancer Res., 1999 Jul.–Aug.,19(4A), 2437–2442.PubMedGoogle Scholar
  12. 12.
    HO C.L., DEHDASHTI F., GRIFFETH L.K., BUSE P.E., BALFE D.M., SIEGEL B.A.—FDG-PET evaluation of indeterminate pancreatic masses.J. Comput. Assist. Tomogr., 1996 May–Jun,20(3), 363–369.PubMedCrossRefGoogle Scholar
  13. 13.
    HUSTINX R., PAULUS P., DAENEN F., DETROZ B., HONORE P., JACQUET N., RIGO P.—Role of positron emission tomography is the evaluation of digestive tract tumors.Rev. Med. Liege, 1999 Dec.,54(12), 925–930.PubMedGoogle Scholar
  14. 14.
    GUPTA N., BRADFIELD H.—Role of positron emission tomography scanning in evaluating gastrointestinal neoplasms.Semin. Nucl. Med., 1996 Jan.,26(1), 65–73.PubMedCrossRefGoogle Scholar
  15. 15.
    IMDAHL A., REINHARDT M.J., NITZSCHE E.U., MIX M., DINGELDEY A., EINERT A., BAIER P., FARTHMANN E.H.—Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences.Langenbecks Arch. Surg., 2000 Mar,385(2), 129–134PubMedCrossRefGoogle Scholar
  16. 16.
    INOKUMA T., TAMAKI N., TORIZUKA T., MAGATA Y., FUJII M., YONEKURA Y., KAJIYAMA T., OHSHIO G., IMAMURA M., KONISHI—Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US.J. Radiology, 1995 May,195(2), 345–352.Google Scholar
  17. 17.
    IWATA Y., SHIOMI S., SASAKI N., JOMURA H., NISHIGUCHI S., SEKI S., KAWABE J., OCHI H.—Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors.Ann. Nucl. Med., 2000 Apr,14(2), 121–126.PubMedCrossRefGoogle Scholar
  18. 18.
    KOLE A.C., PLUKKER J.T., NIEWEG O.E.—Positron emission tomography for staging of oesophageal and gastroesophageal malignancy.Br. J. Cancer, 1998 Aug.,78(4), 521–527.PubMedGoogle Scholar
  19. 19.
    LANDONI C., GIANOLLI L., LUCIGNANI G., MAGNANI P., SAVI A., TRAVAINI L., GILARDI M.C., FAZIO F.— Comparison of dual-head coincidence PET versus ring PET in tumor patients.J. Nucl. Med., 1999 Oct,40(10), 1617–1622.PubMedGoogle Scholar
  20. 20.
    LONNEUX M., SIBOMANA M., PAUWELS S., GREGOIRE V. —Current data and perspectives on positron emission tomography oncology-radiotherapy.Cancer Radiother., 1999 Jul.–Aug.,3(4), 275–288.PubMedGoogle Scholar
  21. 21.
    PHELPS M.E.—PET: the merging of biology and imaging into molecular imaging.J. Nucl. Med., 2000 Aprl.,41(4), 661–681.PubMedGoogle Scholar
  22. 22.
    RANKIN S.C., TAYLOR H., COOK G.J., MASON R.— Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma.Clin. Radiol., 1998 Sep.,53(9), 659–665.PubMedCrossRefGoogle Scholar
  23. 23.
    RESKE S.N., GRILLENBERGER K.G., GLATTING G., PORT M., HILDEBRANDT M., GANSAUGE F., BEGER H.G.—Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma.J. Nucl. Med., 1997 Sep.,38(9), 1344–1348.PubMedGoogle Scholar
  24. 24.
    SCHRODER O., TROJAN J., ZEUZEM S., BAUM R.P.— Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection.Nuklearmedizin, 1998,37 (8), 279–285.PubMedGoogle Scholar
  25. 25.
    STRAUSS L.G.—Positron Emission Tomography: Current Role for Diagnosis and Therapy Monitoring in Oncology.Oncologist, 1997,2(6), 381–388.PubMedGoogle Scholar
  26. 26.
    TORIZUKA T., TAMAKI N., INOKUMA T., MAGATA Y., SASAYAMA S., YONEKURA Y., TANAKA A., YAMAOKA Y., YAMAMOTO K., KONISHI J.—In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET.J. Nucl. Med., 1995 Oct,36(10), 1811–1817.PubMedGoogle Scholar
  27. 27.
    TORIZUKA T., TAMAKI N., INOKUMA T., MAGATA Y., YONEKURA Y., TANAKA A., YAMAOKA Y., YAMAMOTO K., KONISHI J.—Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy.J. Nucl. Med., 1994 Dec.,35(12), 1965–1969.PubMedGoogle Scholar
  28. 28.
    TROJAN J., SCHROEDER O., RAEDLE J., BAUM R.P., HERRMANN G., JACOBI V., ZEUZEM S.—Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.Am. J. Gastroenterol., 1999 Nov,94(11), 3314–3319.PubMedCrossRefGoogle Scholar
  29. 29.
    ZIMNY M., BARES R., FASS J., ADAM G., CREMERIUS U., DOHMEN B., KLEVER P., SABRI O., SCHUMPELICK V., BUELL U.—Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases.Eur. J. Nucl. Med., 1997 Jun,24(6), 678–682.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2000

Authors and Affiliations

  • J. Monteil
    • 2
  • S. Verbeke
    • 2
  • T. Ducloux
    • 2
  • D. Sautereau
    • 2
  • A. Gainant
    • 3
  • B. Descottes
    • 4
  • R. Perdrisot
    • 1
  • J. C. Vandroux
    • 1
  1. 1.Service de Médecine NucléaireCentre Hospitalier UniversitaireLimoges Cedex(France)
  2. 2.Service d'Hépato-Gastro-EntérologieCentre Hospitalier UniversitaireLimoges Cedex(France)
  3. 3.Service de Chirurgie Endocrinienne, Digestive et GénéraleCentre Hospitalier UniversitaireLimoges Cedex(France)
  4. 4.Service de Chirurgie Viscérale et TransplantationsCentre Hospitalier UniversitaireLimoges Cedex(France)

Personalised recommendations